Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Insulet Corporation, AtriCure or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Insulet Corporation, AtriCure and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Insulet Corporation, AtriCure and Inc.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula’s to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Latest Health Care Equipment & Supplies and Insulet Corporation, AtriCure, Inc. Stock News

As of August 20, 2026, Insulet Corporation had a $10.2 billion market capitalization, compared to the Health Care Equipment & Supplies median of $407.7 million. Insulet Corporation’s stock is NA in 2026, NA in the previous five trading days and down 55.15% in the past year.

Currently, Insulet Corporation’s price-earnings ratio is 27.7. Insulet Corporation’s trailing 12-month revenue is $3.1 billion with a 12.3% net profit margin. Year-over-year quarterly sales growth most recently was 23.5%. Analysts expect adjusted earnings to reach $6.503 per share for the current fiscal year. Insulet Corporation does not currently pay a dividend.

Currently, AtriCure, Inc.’s price-earnings ratio is 225.1. AtriCure, Inc.’s trailing 12-month revenue is $569.6 million with a 1.9% net profit margin. Year-over-year quarterly sales growth most recently was 12.9%. Analysts expect adjusted earnings to reach $0.284 per share for the current fiscal year. AtriCure, Inc. does not currently pay a dividend.

How We Compare Insulet Corporation, AtriCure and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Insulet Corporation, AtriCure and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Insulet Corporation, AtriCure and Inc. Growth Grades

Company	Ticker	Growth
Insulet Corporation	PODD	D
AtriCure, Inc.	ATRC	D

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Insulet Corporation has a Growth Score of 40, which is Weak. AtriCure, Inc. has a Growth Score of 37, which is Weak.

The Growth Stock Winner: No Clear Winner

Neither Insulet Corporation, AtriCure or Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Insulet Corporation, AtriCure or Inc. is the better investment when it comes to sustainable growth.

Insulet Corporation, AtriCure and Inc.’s Momentum Grades

Company	Ticker	Momentum
Insulet Corporation	PODD	F
AtriCure, Inc.	ATRC	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Insulet Corporation has a Momentum Score of 13, which is Very Weak. AtriCure, Inc. has a Momentum Score of 89, which is Very Strong.

The Momentum Grade Winner: AtriCure, Inc.

As you can clearly see from the Momentum Grade breakdown above, AtriCure, Inc. is considered to have stronger momentum compared to Insulet Corporation. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, AtriCure, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Insulet Corporation, AtriCure and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Insulet Corporation	PODD	B
AtriCure, Inc.	ATRC	A

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Insulet Corporation has a Earnings Estimate Score of 63, which is Positive. AtriCure, Inc. has a Earnings Estimate Score of 83, which is Very Positive.

The Earnings Estimate Revisions Grade Winner: AtriCure, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, AtriCure, Inc. has a better Earnings Estimate Revisions Grade than Insulet Corporation. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, AtriCure, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Insulet Corporation, AtriCure and Inc. Grades

In addition to Growth, Estimate Revisions and Momentum, A+ Investor also provides grades for Value and Quality.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Insulet Corporation, AtriCure and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Insulet Corporation, AtriCure or Inc. Stock?

Overall, Insulet Corporation stock has a Growth Score of 40, Momentum Score of 13 and Estimate Revisions Score of 63.

AtriCure, Inc. stock has a Growth Score of 37, Momentum Score of 89 and Estimate Revisions Score of 83.

Comparing Insulet Corporation, AtriCure and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.